Hyperuricemia is Independently Associated with Coronary Heart Disease and Renal Dysfunction in Patients with Type 2 Diabetes Mellitus
Overview
Authors
Affiliations
Aims: To investigate the relationship between hyperuricemia (HUA) and the clinical backgrounds in Japanese patients with type 2 diabetes mellitus.
Methods: After a cross-sectional study evaluating the association of HUA with the clinical characteristics in 1,213 patients with type 2 diabetes mellitus, the estimated glomerular filtration rate (eGFR) and the incidence of diabetic macroangiopathies was investigated in a prospective observational study in 1,073 patients during a 3.5 year period. HUA was defined by serum uric acid levels >327 μmol/L or as patients using allopurinol.
Results: The frequency of HUA was significantly higher in the diabetic patients (32% in men and 15% in women) than in the normal controls (14% in men and 1% in women). In total, HUA was found in 299 (25%) of the patients during the cross-sectional study. Even after adjusting for sex, drinking status, treatment for diabetes mellitus, body mass index, hypertension, use of diuretics, hyperlipidemia, HbA1c and/or the eGFR, the HUA was independently associated with some diabetic complications. The eGFR was significantly reduced in HUA patients compared to those with normouricemia in the 12 months after observation was started. HUA was also an independent risk factor for coronary heart disease even after adjustment in the Cox proportional hazard model.
Conclusions: HUA is a associated with diabetic micro- and macroangiopathies. HUA is a predictor of coronary heart disease and renal dysfunction in patients with type 2 diabetes mellitus. However, the influence of HUA is considered to be limited.
Matsumoto S, Ito H, Inoue H, I C, Miura S, Antoku S JMA J. 2024; 7(4):571-579.
PMID: 39513071 PMC: 11543293. DOI: 10.31662/jmaj.2024-0128.
Abdel K, Kalluvya S, Sadiq A, Ashir A, Masikini P Clin Med Insights Endocrinol Diabetes. 2024; 17:11795514241274694.
PMID: 39220387 PMC: 11365026. DOI: 10.1177/11795514241274694.
Zheliabina O, Eliseev M, Glukhova S, Nasonov E Dokl Biochem Biophys. 2023; 511(1):195-202.
PMID: 37833606 PMC: 10739371. DOI: 10.1134/S1607672923700321.
Immunomodulation and immunopharmacology in heart failure.
Markousis-Mavrogenis G, Baumhove L, Al-Mubarak A, Aboumsallem J, Bomer N, Voors A Nat Rev Cardiol. 2023; 21(2):119-149.
PMID: 37709934 DOI: 10.1038/s41569-023-00919-6.
Sodium glucose cotransporter 2 inhibitors and gout risk: a sequence symmetry analysis.
Wood D, Waterbury N, Lund B Clin Rheumatol. 2023; 42(9):2469-2475.
PMID: 37264145 DOI: 10.1007/s10067-023-06647-z.